Extracellular vesicles as advanced therapeutics for the resolution of organ fibrosis: Current progress and future perspectives
Authors:
Open Access
- 20 October 2022
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 1042983
Abstract
Organ fibrosis is a serious health challenge worldwide, and its global incidence and medical burden are increasing dramatically each year. Fibrosis can occur in nearly all major organs and ultimately lead to organ dysfunction. However, current clinical treatments cannot slow or reverse the progression of fibrosis to end-stage organ failure, and thus advanced anti-fibrotic therapeutics are urgently needed. As a type of naturally derived nanovesicle, native extracellular vesicles (EVs) from multiple cell types (e.g., stem cells, immune cells, and tissue cells) have been shown to alleviate organ fibrosis in many preclinical models through multiple effective mechanisms, such as anti-inflammation, pro-angiogenesis, inactivation of myofibroblasts, and fibrinolysis of ECM components. Moreover, the therapeutic potency of native EVs can be further enhanced by multiple engineering strategies, such as genetic modifications, preconditionings, therapeutic reagent-loadings, and combination with functional biomaterials. In this review, we briefly introduce the pathology and current clinical treatments of organ fibrosis, discuss EV biology and production strategies, and particularly focus on important studies using native or engineered EVs as interventions to attenuate tissue fibrosis. This review provides insights into the development and translation of EV-based nanotherapies into clinical applications in the future.Keywords
Funding Information
- National Natural Science Foundation of China (32071453, 31871001, 81571808, 32001011)
- Fundamental Research Funds for the Central Universities
This publication has 179 references indexed in Scilit:
- Extracellular vesicles: Exosomes, microvesicles, and friendsJournal of Cell Biology, 2013
- Nanoparticle tracking analysis monitors microvesicle and exosome secretion from immune cellsImmunology, 2012
- The miR-200 family regulates TGF-β1-induced renal tubular epithelial to mesenchymal transition through Smad pathway by targeting ZEB1 and ZEB2 expressionAmerican Journal of Physiology-Renal Physiology, 2012
- Activation of canonical Wnt signalling is required for TGF-β-mediated fibrosisNature Communications, 2012
- Chemokines in Renal InjuryJournal of the American Society of Nephrology, 2011
- The Crumbs Complex Couples Cell Density Sensing to Hippo-Dependent Control of the TGF-β-SMAD PathwayDevelopmental Cell, 2010
- Cellular and molecular mechanisms of fibrosisThe Journal of Pathology, 2007
- Regenerative Potential of Cardiosphere-Derived Cells Expanded From Percutaneous Endomyocardial Biopsy SpecimensCirculation, 2007
- Liver fibrosisJournal of Clinical Investigation, 2005
- Smad-dependent and Smad-independent pathways in TGF-β family signallingNature, 2003